title: Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants.
abstract: OBJECTIVE
  A prospective observational study to investigate hematologic alterations during the first 3 months of life in HIV-exposed uninfected infants subjected to antiretroviral medication before and after birth.
  
  
  METHODS
  Two hundred twenty-one consecutive uninfected infants born to HIV-positive mothers on antiretroviral medication during pregnancy were included. Perinatal transmission prophylaxis comprised zidovudine (ZDV) administered intravenously intrapartum and 10 days after birth. Blood counts and differentials were determined at birth and at 2, 4, 6, and 12 weeks of age, and hematologic toxicity was graded according to pediatric toxicity scales. Data were analyzed according to the kind of prenatal medication (ZDV alone or with another nucleoside reverse transcriptase inhibitor [NRTI] vs. highly active antiretroviral therapy [HAART]).
  
  
  RESULTS
  Median hemoglobin was significantly lower in HAART-exposed newborns from birth (P = 0.004) until day 28. During follow-up, 119 (53.8%) infants had anemia grade 2 or higher on at least 1 occasion; 16 (7.2%) received red blood cell transfusion at 23 (range: 1-56) days of age. Neutropenia grade 2 or higher occurred in 106 (48.0%) infants at least once; 8 infants had staphylococcal infections, and 2 infections were severe. After adjustment for possible confounders (prematurity, birth weight, ethnicity, gender, duration of maternal antiretroviral therapy, maternal Centers for Disease Control and Prevention stage, and maternal illicit drug use), HAART exposure was the only independent risk factor for anemia (odds ratio [OR] = 2.22, 95% confidence interval [CI]: 1.06 to 4.64; P = 0.034) and neutropenia (OR = 2.15, CI: 1.02 to 4.55; P = 0.045).
  
  
  CONCLUSIONS
  Antiretroviral transmission prophylaxis is associated with significant anemia and neutropenia in HIV-uninfected infants during the first 3 months of life. Anemia was more profound in HAART-exposed infants.
authors.affiliation: Charité, Department of Pediatric Pneumology and Immunology, University Medicine Berlin, Berlin, Germany. cornelia.feiterna-sperling@charite.de
authors.forename: Cornelia
authors.initials: C
authors.lastname: Feiterna-Sperling
authors.forename: Katharina
authors.initials: K
authors.lastname: Weizsaecker
authors.forename: Christoph
authors.initials: C
authors.lastname: Bührer
authors.forename: Simone
authors.initials: S
authors.lastname: Casteleyn
authors.forename: Andrea
authors.initials: A
authors.lastname: Loui
authors.forename: Thomas
authors.initials: T
authors.lastname: Schmitz
authors.forename: Volker
authors.initials: V
authors.lastname: Wahn
authors.forename: Michael
authors.initials: M
authors.lastname: Obladen
mesh_terms: D000740:Anemia / Q000145:classification / Q000473:pathology; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D016001:Confidence Intervals; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000517:prevention & control / Q000635:transmission*; D015497:HIV-1; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D009503:Neutropenia / Q000145:classification / Q000473:pathology; D016017:Odds Ratio; D018743:Perinatal Care; D011247:Pregnancy; D011446:Prospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D015215:Zidovudine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine